Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 17.
doi: 10.1038/s41416-024-02684-w. Online ahead of print.

The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications

Kaina Chen #  1   2 , Timothy W H Shuen #  3 , Pierce K H Chow  4   5   6
Affiliations
Review

The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications

Kaina Chen et al. Br J Cancer. .

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide. The emergence of combination therapy, atezolizumab (anti-PDL1, immune checkpoint inhibitor) and bevacizumab (anti-VEGF) has revolutionised the management of HCC. Despite this breakthrough, the best overall response rate with first-line systemic therapy is only about 30%, owing to intra-tumoural heterogeneity, complex tumour microenvironment and the lack of predictive biomarkers. Many groups have attempted to classify HCC based on the immune microenvironment and have consistently observed better outcomes in immunologically "hot" HCC. We summarised possible mechanisms of tumour immune evasion based on the latest literature and the rationale for combination/sequential therapy to improve treatment response. Lastly, we proposed future strategies and therapies to overcome HCC immune evasion to further improve treatment outcomes of HCC.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. - DOI - PubMed
    1. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–606. - PubMed - PMC - DOI
    1. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72:250–61. - PubMed - PMC - DOI
    1. Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, et al. Real-world data on clinical outcomes of patients with liver cancer: a prospective validation of the national cancer centre Singapore consensus guidelines for the management of hepatocellular carcinoma. Liver Cancer. 2021;10:224–39. - PubMed - PMC - DOI
    1. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35:2155–66. - PubMed - PMC - DOI

LinkOut - more resources